title: Efficacy of prophylactic minocycline treatment for skin toxicities induced by erlotinib plus gemcitabine in patients with advanced pancreatic cancer: a retrospective study.
abstract: BACKGROUND
  Erlotinib has been reported as being associated with a high incidence of skin toxicities such as acneiform rash, paronychia, and xerosis.
  
  
  OBJECTIVE
  The aim of this study was to evaluate the efficacy of prophylactic minocycline treatment for the skin toxicities induced by erlotinib as compared with deferred minocycline treatment in patients with pancreatic cancer treated with erlotinib plus gemcitabine.
  
  
  METHODS
  A total of 96 patients were studied retrospectively, of whom 44 received prophylactic minocycline between August 2012 and June 2013 and 52 received deferred minocycline treatment between August 2011 and July 2012 at the National Cancer Center Hospital East, Kashiwa, Japan. In the prophylactic minocycline group, 200 mg/day oral minocycline was prophylactically administered during the treatment period.
  
  
  RESULTS
  The incidence rate of acneiform rash and xerosis of any grade during the first 6 weeks of treatment was significantly reduced in the prophylactic minocycline group compared with the deferred minocycline treatment group (47.7 vs. 80.8%, p<0.001; 2.3 vs. 19.2%, p=0.01). Multivariate analysis identified prophylactic minocycline as a significant independent factor associated with the incidence of acneiform rash and xerosis of any severity (odds ratio [OR] 0.16, 95% confidence interval [CI] 0.06-0.46, p<0.001; OR 0.11, 95% CI 0.01-0.90, p=0.04).
  
  
  CONCLUSIONS
  Prophylactic minocycline appears to be useful for the management of erlotinib-related acneiform rash and xerosis during chemotherapy in patients with advanced pancreatic cancer.
authors: Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Japan.
authors: Akira
authors: A
authors: Shinohara
authors: Masafumi
authors: M
authors: Ikeda
authors: Hiroyuki
authors: H
authors: Okuyama
authors: Misaki
authors: M
authors: Kobayashi
authors: Hideki
authors: H
authors: Funazaki
authors: Shuichi
authors: S
authors: Mitsunaga
authors: Satoshi
authors: S
authors: Shimizu
authors: Izumi
authors: I
authors: Ohno
authors: Hideaki
authors: H
authors: Takahashi
authors: Yasuhiko
authors: Y
authors: Ichida
authors: Kunio
authors: K
authors: Takahashi
authors: Takuji
authors: T
authors: Okusaka
authors: Shinichiro
authors: S
authors: Saitoh
mesh_terms: D017486:Acneiform Eruptions / Q000139:chemically induced / Q000517:prevention & control*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D003879:Dermatologic Agents / Q000008:administration & dosage*; D003875:Drug Eruptions / Q000517:prevention & control; D000069347:Erlotinib Hydrochloride / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008911:Minocycline / Q000008:administration & dosage*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies; D000093542:Gemcitabine
chemical_list: D003879:Dermatologic Agents; D003841:Deoxycytidine; D000069347:Erlotinib Hydrochloride; D008911:Minocycline; D000093542:Gemcitabine